Skip to main content
Midas Edge

ARROWHEAD PHARMACEUTICALS, INC.

For the period ended Dec 31, 2025. Filed Feb 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2025 · Filed Feb 5, 2026

ARWR$49.00-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except per share amounts)

Three Months Ended December 31,
20252024
Revenue$264,033$2,500
Operating expenses:
Research and development177,203137,002
General and administrative46,02126,910
Total operating expenses223,224163,912
Operating income (loss)40,809(161,412)
Other (expense) income:
Interest income9,6907,602
Interest expense(22,505)(21,646)
Other, net277341
Total other expense(12,538)(13,703)
Income (loss) before income tax expense and noncontrolling interest28,271(175,115)
Income tax expense29103
Net income (loss) including noncontrolling interest$28,242$(175,218)
Net loss attributable to noncontrolling interest, net of tax(2,569)(2,133)
Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.$30,811$(173,085)
Net income (loss) per share attributable to Arrowhead Pharmaceuticals, Inc.:
Basic$0.22$(1.39)
Diluted$0.22$(1.39)
Weighted-average shares used in calculating
Basic137,039124,848
Diluted140,706124,848
Other comprehensive income (loss), net of tax:
Unrealized gains (losses) on available-for-sale securities146(507)
Foreign currency translation adjustments110(106)
Comprehensive loss attributed to noncontrolling interest$(2,569)$(2,133)
Other comprehensive income (loss)$28,498$(175,831)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.